SCHEMBL13077903

SCHEMBL13077903

Cc1cccc(Cl)c1NC(=O)Nc1ccc(-c2cc(C3CC3)nc3c2c(N)nn3C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 10/20 0.48
CSF1R P07333 8/20 0.48
BLK P51451 7/20 0.48
KDR P35968 14/20 0.46
FLT3 P36888 12/20 0.46
FLT1 P17948 7/20 0.46
FLT4 P35916 7/20 0.46
LYN P07948 6/20 0.46
LCK P06239 6/20 0.46
ABL1 P00519 3/20 0.46
SRC P12931 3/20 0.46
FYN P06241 2/20 0.46
AURKB Q96GD4 4/20 0.44
AURKA O14965 3/20 0.44
DYRK3 O43781 3/20 0.44
ROCK2 O75116 3/20 0.44
MAP4K4 O95819 3/20 0.44
RET P07949 3/20 0.44
MET P08581 3/20 0.44
FGFR1 P11362 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041777 0.95 KIT (0.49) KITCSF1RBLKKDRFLT3
SCHEMBL13041771 0.88 KDR (0.47) KITCSF1RBLKKDRFLT3
SCHEMBL13041764 0.88 KDR (0.51) KITCSF1RBLKKDRFLT3
SCHEMBL13041778 0.87 KIT (0.52) KITCSF1RBLKKDRFLT3
SCHEMBL13041768 0.87 CSF1R (0.52) KITCSF1RBLKKDRFLT3
SCHEMBL13041758 0.86 KDR (0.50) KITCSF1RBLKKDRFLT3
SCHEMBL13041765 0.86 KDR (0.61) KITCSF1RBLKKDRFLT3
SCHEMBL13041774 0.86 KIT (0.50) KITCSF1RBLKKDRFLT3
SCHEMBL13041755 0.86 CSF1R (0.53) KITCSF1RBLKKDRFLT3
SCHEMBL13041781 0.86 KIT (0.58) KITCSF1RBLKKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK KIT 22/4885CSF1R 918/4885BLK 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.